Clinical Trials Browser

Phase 2 × Completed × isatuximab × Clear all

Natural Killer/T-cell Lymphoma

NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT04939844 2025-03-20

REST

Phase 2 Completed

51 enrolled

Plasma cell

Multiple Myeloma

Clinical Trials

ICING

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

REST